Share on StockTwits
 

Alexion Pharmaceuticals (NASDAQ:ALXN) Director Joseph A. Madri sold 30,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $159.00, for a total transaction of $4,770,000.00. Following the completion of the transaction, the director now directly owns 179,217 shares in the company, valued at approximately $28,495,503. The transaction was disclosed in a document filed with the SEC, which is available at this link.

ALXN has been the subject of a number of recent research reports. Analysts at Deutsche Bank raised their price target on shares of Alexion Pharmaceuticals from $125.00 to $205.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday. They now have a $189.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday, February 4th. They now have a $170.00 price target on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $159.61.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, January 30th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.